- Home
- HRMY vs NMM Comparison
HRMY vs NMM Comparison
Compare HRMY & NMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- NMM
- Stock Information
- Founded
- HRMY 2017
- NMM 2007
- Country
- HRMY United States
- NMM Greece
- Employees
- HRMY N/A
- NMM N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- NMM Marine Transportation
- Sector
- HRMY Health Care
- NMM Consumer Discretionary
- Exchange
- HRMY Nasdaq
- NMM Nasdaq
- Market Cap
- HRMY 2.0B
- NMM 1.1B
- IPO Year
- HRMY 2020
- NMM 2007
- Fundamental
- Price
- HRMY $32.16
- NMM $38.63
- Analyst Decision
- HRMY Strong Buy
- NMM Strong Buy
- Analyst Count
- HRMY 9
- NMM 1
- Target Price
- HRMY $54.22
- NMM $80.00
- AVG Volume (30 Days)
- HRMY 620.8K
- NMM 99.9K
- Earning Date
- HRMY 08-05-2025
- NMM 08-19-2025
- Dividend Yield
- HRMY N/A
- NMM 0.52%
- EPS Growth
- HRMY 13.13
- NMM N/A
- EPS
- HRMY 2.62
- NMM 11.16
- Revenue
- HRMY $744,852,000.00
- NMM $1,319,623,000.00
- Revenue This Year
- HRMY $20.10
- NMM N/A
- Revenue Next Year
- HRMY $18.01
- NMM $7.93
- P/E Ratio
- HRMY $12.27
- NMM $3.46
- Revenue Growth
- HRMY 20.62
- NMM 0.28
- 52 Week Low
- HRMY $26.47
- NMM $28.37
- 52 Week High
- HRMY $41.61
- NMM $65.89
- Technical
- Relative Strength Index (RSI)
- HRMY 43.25
- NMM 48.79
- Support Level
- HRMY $31.70
- NMM $36.62
- Resistance Level
- HRMY $33.69
- NMM $39.41
- Average True Range (ATR)
- HRMY 0.89
- NMM 1.18
- MACD
- HRMY -0.10
- NMM -0.24
- Stochastic Oscillator
- HRMY 37.30
- NMM 32.28
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.